Key result
In dialysis patients, adiponectin levels correlated strongly with body mass index (r = -0.403, p < 0.001) and to a lesser extent with left ventricular mass index (r = 0.296, p = 0.005).
Why the study?
Does adiponectin correlate with left ventricular mass and body mass index in dialysis patients?
Cross-Sectional (n=144)
No
Does adiponectin correlate with left ventricular mass and body mass index in dialysis patients?
Effect estimate: r = -0.403
p-value: p=<0.001
In dialysis patients, adiponectin correlates more strongly with anthropometric measurements like BMI than with left ventricular mass, suggesting it reflects an ongoing catabolic process rather than primary changes in ventricular function.
Adiponectin may mark catabolism over LV remodeling in dialysis; hypothesis-generating for its cardiac role, needing prospective validation.
BACKGROUND: Adiponectin is a serum protein produced by adipose tissue which exerts anti-inflammatory, anti-diabetic and anti-atherosclerotic properties, hence is considered a cardio-protective marker. With the current uncertain role of adiponectin in dialysis patients to the aim of this study was to investigate its relationship with left ventricular (LV) structure and function in these patients. METHODS: This study included 89 (age 56 ± 13 years, 43% male) patients treated with regular dialysis for > 6 months, and 55 control subjects with normal renal function. A complete two-dimensional, M-mode and tissue-Doppler echocardiographic study, and biochemical blood analyses, adiponectin and anthropometric parameters were obtainedon the same day. RESULTS: Dialysis patients had lower body mass index (BMI) and lower body surface area (BSA) (p < 0.001 for both), lower waist/hips ratio (p = 0.005), higher LV mass index (LVMI, p < 0.001), higher adiponectin level (p < 0.001) and LV end-systolic volume (p = 0.003), lower LV ejection fraction (p = 0.006), longer isovolumic relaxation time (p < 0.001), lower mean LV strain (p = 0.002), larger left atrium volume (p = 0.022) and lower left atrium emptying fraction (p = 0.026), compared to controls. In dialysis patients, adiponectin correlated with waist circumference (r = -0.427, p < 0.001), BMI (r = -0.403, p < 0.001) and BSA (r = -0.480, p < 0.001), and to a lesser extent with LVMI (r = 0.296, p = 0.005), waist/hips ratio (r = -0.222, p = 0.037) and total cholesterol (r = -0.292, p = 0.013). But in controls, it correlated only modestly with age (r = 0.304, p = 0.024), hemoglobin (r = 0.371, p = 0.005), high density lipoprotein cholesterol (r = 0.315, p = 0.019) and LVMI (r = 0.277, p = 0.043). CONCLUSIONS: It seems that in dialysis patients, adiponectin modest correlation with anthropometric measurements suggests an ongoing catabolic process rather than a change in ventricular function.
No takes yet. Share an insight, caveat, or question.
Poniku et al. (2017) conducted a cross-sectional in End-stage renal disease on dialysis (n=144). Adiponectin levels vs. Controls with normal renal function was evaluated on Correlation between adiponectin and body mass index (BMI) in dialysis patients (r = -0.403, p=<0.001). In dialysis patients, adiponectin levels correlated strongly with body mass index (r = -0.403, p < 0.001) and to a lesser extent with left ventricular mass index (r = 0.296, p = 0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: